INM - סך החוב של החברה InMed Pharmaceuticals Inc.

The InMed Pharmaceuticals (INM) business model is based on the production of scarce cannabinoids for medical use, focusing on glaucoma therapy and dermatological pathologies. A team of top-tier biochemists is retained through their work in a unique segment and stable investments. The price action for specific debt is fixed at 0.00. Diversified raw material supply channels, secured by long-term contracts, ensure the uninterrupted production of drugs for clinics.

For a biotech company in the early research stage, such as InMed Pharmaceuticals (INM), access to venture capital is a critical survival factor in the absence of stable revenue. This metric aggregates total liabilities, allowing for an assessment of the business's actual resilience by comparing the debt load to market value, which is clearly demonstrated by the current credit debt within the loan repayment dynamics.